Symbols / ANVS
ANVS Chart
About
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 71.03M |
| Enterprise Value | 55.74M | Income | -24.88M | Sales | — |
| Book/sh | 0.65 | Cash/sh | 0.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -2.35 | PEG | — |
| P/S | — | P/B | 4.11 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 4.09 |
| Current Ratio | 4.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.43 | EPS next Y | -1.14 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -105.88% |
| ROE | -246.14% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.50M |
| Shs Float | 22.41M | Short Float | 12.38% | Short Ratio | 5.49 |
| Short Interest | — | 52W High | 5.50 | 52W Low | 1.11 |
| Beta | 1.31 | Avg Volume | 701.31K | Volume | 698.92K |
| Target Price | $13.75 | Recom | Strong_buy | Prev Close | $2.39 |
| Price | $2.68 | Change | 12.13% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.75
Mean price target
2. Current target
$2.68
Latest analyst target
3. DCF / Fair value
$-10.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.68
Low
$8.00
High
$20.00
Mean
$13.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2025-09-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-06-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-05-15 | main | Canaccord Genuity | Buy → Buy | $17 |
| 2025-02-10 | down | D. Boral Capital | Buy → Hold | — |
| 2024-11-11 | main | D. Boral Capital | Buy → Buy | $21 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-25 | up | Maxim Group | Hold → Buy | $25 |
| 2024-08-15 | main | EF Hutton | Buy → Buy | $21 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-13 | init | EF Hutton | — → Buy | $21 |
| 2024-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-07-11 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-07-02 | reit | Rodman & Renshaw | Buy → Buy | $67 |
| 2024-06-12 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-06-04 | init | Rodman & Renshaw | — → Buy | $67 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-04-30 | main | Canaccord Genuity | Buy → Buy | $26 |
| 2024-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $30 |
- $ANVS stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 13 Jan 2026 08
- $6M Offering: Annovis Sells 4M Shares in Registered Direct Offering for Working Capital - Stock Titan Fri, 10 Oct 2025 07
- Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS Mon, 23 Feb 2026 07
- Annovis Bio director Hoffman buys $69.9k in ANVS stock - Investing.com Fri, 21 Nov 2025 08
- We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance Sun, 22 Jun 2025 07
- Canaccord Genuity Maintains Annovis Bio (ANVS) Buy Recommendation - Nasdaq ue, 30 Sep 2025 07
- $ANVS stock is up 4% today. Here's what we see in our data. - Quiver Quantitative Fri, 28 Nov 2025 08
- Annovis Bio (NYSE: ANVS) prices $3.4M registered direct at $2.05 per share - Stock Titan Mon, 27 Oct 2025 07
- Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling - Investing.com Mon, 24 Nov 2025 08
- Annovis Bio Stock (ANVS) Opinions on Phase 3 Alzheimer’s Trial Progress - Quiver Quantitative Wed, 12 Nov 2025 08
- Annovis Bio (NYSE: ANVS) to share buntanetap cognitive data in PD, AD at 2025 PSG meeting - Stock Titan Wed, 03 Dec 2025 08
- $ANVS stock is down 8% today. Here's what we see in our data. - Quiver Quantitative hu, 11 Dec 2025 08
- Insider Purchase: Director at $ANVS Buys 15,000 Shares - Quiver Quantitative ue, 18 Nov 2025 08
- Insider Purchase: President & CEO of $ANVS Buys 97,561 Shares - Quiver Quantitative Wed, 12 Nov 2025 08
- ANNOVIS BIO -REDH Earnings Results: $ANVS Reports Quarterly Earnings - Quiver Quantitative ue, 12 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 45000 | 193794 | — | Purchase at price 4.24 - 4.34 per share. | HOFFMAN MICHAEL B | Director | — | 2025-12-08 00:00:00 | D |
| 1 | 39200 | 159886 | — | Purchase at price 3.85 - 4.15 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-24 00:00:00 | D |
| 2 | 39200 | 159886 | — | Purchase at price 3.85 - 4.15 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-24 00:00:00 | D |
| 3 | 20000 | 69900 | — | Purchase at price 3.49 - 3.50 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-21 00:00:00 | D |
| 4 | 15000 | 31650 | — | Purchase at price 2.11 per share. | HOFFMAN MICHAEL B | Director | — | 2025-11-14 00:00:00 | D |
| 5 | 97561 | 200000 | — | Purchase at price 2.05 per share. | MACCECCHINI MARIA-LUISA | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 6 | 975610 | 2000000 | — | Purchase at price 2.05 per share. | HOFFMAN MICHAEL B | Director | — | 2025-10-28 00:00:00 | D |
| 7 | 7142 | 1000 | — | Conversion of Exercise of derivative security at price 0.14 per share. | BRUCK CLAUDINE | Director | — | 2025-09-10 00:00:00 | D |
| 8 | 15000 | 34350 | — | Stock Award(Grant) at price 2.28 - 2.30 per share. | HOFFMAN MICHAEL B | Director | — | 2025-08-29 00:00:00 | D |
| 9 | 18645 | 48280 | — | Stock Award(Grant) at price 2.57 - 2.60 per share. | HOFFMAN MICHAEL B | Director | — | 2025-08-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -30.32M | -33.20M | -25.51M | -14.50M |
| TotalUnusualItems | 3.63M | -11.84M | ||
| TotalUnusualItemsExcludingGoodwill | 3.63M | -11.84M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.59M | -56.20M | -25.33M | -14.49M |
| EBITDA | -26.69M | -45.04M | -25.51M | -14.50M |
| EBIT | -26.69M | -45.04M | -25.51M | -14.50M |
| NetInterestIncome | -1.52M | 667.90K | 182.71K | 13.34K |
| InterestIncome | 331.85K | 667.90K | 182.71K | 13.34K |
| NormalizedIncome | -28.22M | -44.37M | -25.33M | -14.49M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.59M | -56.20M | -25.33M | -14.49M |
| TotalExpenses | 26.69M | 45.04M | 25.51M | 14.50M |
| TotalOperatingIncomeAsReported | -26.69M | -45.04M | -25.51M | -14.54M |
| DilutedAverageShares | 12.24M | 9.02M | 8.16M | 7.63M |
| BasicAverageShares | 12.18M | 9.02M | 8.16M | 7.63M |
| DilutedEPS | -2.31 | -6.23 | -3.10 | -1.90 |
| BasicEPS | -2.02 | -6.23 | -3.10 | -1.90 |
| DilutedNIAvailtoComStockholders | -28.22M | -56.20M | -25.33M | -14.49M |
| AverageDilutionEarnings | -3.63M | 0.00 | ||
| NetIncomeCommonStockholders | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncome | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncomeIncludingNoncontrollingInterests | -24.59M | -56.20M | -25.33M | -14.49M |
| NetIncomeContinuousOperations | -24.59M | -56.20M | -25.33M | -14.49M |
| PretaxIncome | -24.59M | -56.20M | -25.33M | -14.49M |
| OtherIncomeExpense | 3.63M | -11.84M | ||
| GainOnSaleOfSecurity | 3.63M | -11.84M | ||
| NetNonOperatingInterestIncomeExpense | -1.52M | 667.90K | 182.71K | 13.34K |
| TotalOtherFinanceCost | 1.85M | |||
| InterestIncomeNonOperating | 331.85K | 667.90K | 182.71K | 13.34K |
| OperatingIncome | -26.69M | -45.04M | -25.51M | -14.50M |
| OperatingExpense | 26.69M | 45.04M | 25.51M | 14.50M |
| OtherOperatingExpenses | -36.75K | |||
| ProvisionForDoubtfulAccounts | 0.00 | 0.00 | 0.00 | |
| ResearchAndDevelopment | 20.00M | 38.79M | 16.52M | 8.48M |
| SellingGeneralAndAdministration | 6.70M | 6.24M | 9.00M | 6.06M |
| GeneralAndAdministrativeExpense | 6.70M | 6.24M | 9.00M | 6.06M |
| OtherGandA | 6.70M | 6.24M | 9.00M | 6.06M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 14.14M | 10.52M | 8.16M | 8.10M |
| ShareIssued | 14.14M | 10.52M | 8.16M | 8.10M |
| TangibleBookValue | 9.31M | -7.75M | 28.32M | 44.49M |
| InvestedCapital | 9.31M | -7.75M | 28.32M | 44.49M |
| WorkingCapital | 10.04M | 5.93M | 28.32M | 44.49M |
| NetTangibleAssets | 9.31M | -7.75M | 28.32M | 44.49M |
| CommonStockEquity | 9.31M | -7.75M | 28.32M | 44.49M |
| TotalCapitalization | 9.31M | -7.75M | 28.32M | 44.49M |
| TotalEquityGrossMinorityInterest | 9.31M | -7.75M | 28.32M | 44.49M |
| StockholdersEquity | 9.31M | -7.75M | 28.32M | 44.49M |
| RetainedEarnings | -134.85M | -110.26M | -54.05M | -28.73M |
| AdditionalPaidInCapital | 144.16M | 102.51M | 82.38M | 73.22M |
| CapitalStock | 1.41K | 1.05K | 816.00 | 810.00 |
| CommonStock | 1.41K | 1.05K | 816.00 | 810.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.62M | 17.96M | 7.70M | 1.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 737.00K | 13.68M | 0.00 | 0.00 |
| DerivativeProductLiabilities | 737.00K | 13.68M | 0.00 | |
| CurrentLiabilities | 3.88M | 4.28M | 7.70M | 1.51M |
| PayablesAndAccruedExpenses | 3.88M | 4.28M | 7.70M | 1.51M |
| CurrentAccruedExpenses | 1.58M | 2.99M | 3.74M | 818.44K |
| Payables | 2.31M | 1.29M | 3.96M | 688.07K |
| AccountsPayable | 2.31M | 1.29M | 3.96M | 688.07K |
| TotalAssets | 13.93M | 10.21M | 36.02M | 46.00M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 13.93M | 10.21M | 36.02M | 46.00M |
| PrepaidAssets | 3.37M | 4.45M | 7.64M | 315.46K |
| CashCashEquivalentsAndShortTermInvestments | 10.55M | 5.75M | 28.38M | 45.69M |
| CashAndCashEquivalents | 10.55M | 5.75M | 28.38M | 45.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -21.89M | -39.97M | -17.31M | -9.13M |
| IssuanceOfCapitalStock | 18.67M | 16.89M | 0.00 | 46.65M |
| EndCashPosition | 10.55M | 5.75M | 28.38M | 45.69M |
| BeginningCashPosition | 5.75M | 28.38M | 45.69M | 8.07M |
| ChangesInCash | 4.80M | -22.62M | -17.31M | 37.61M |
| FinancingCashFlow | 26.69M | 17.34M | 4.61K | 46.74M |
| CashFlowFromContinuingFinancingActivities | 26.69M | 17.34M | 4.61K | 46.74M |
| ProceedsFromStockOptionExercised | 8.03M | 458.38K | 4.61K | 95.10K |
| NetCommonStockIssuance | 18.67M | 16.89M | 0.00 | 46.65M |
| CommonStockIssuance | 18.67M | 16.89M | 0.00 | 46.65M |
| OperatingCashFlow | -21.89M | -39.97M | -17.31M | -9.13M |
| CashFlowFromContinuingOperatingActivities | -21.89M | -39.97M | -17.31M | -9.13M |
| ChangeInWorkingCapital | 681.71K | -228.60K | -1.14M | 657.35K |
| ChangeInPayablesAndAccruedExpense | -398.12K | -3.42M | 6.19M | 928.13K |
| ChangeInAccruedExpense | -1.41M | -751.01K | 2.92M | 581.92K |
| ChangeInPayable | 1.01M | -2.67M | 3.27M | 346.22K |
| ChangeInAccountPayable | 1.01M | -2.67M | 3.27M | 346.22K |
| ChangeInPrepaidAssets | 1.08M | 3.19M | -7.33M | -270.79K |
| ChangeInReceivables | 0.00 | |||
| OtherNonCashItems | 1.80M | |||
| StockBasedCompensation | 3.84M | 4.63M | 9.15M | 4.70M |
| OperatingGainsLosses | -3.63M | 11.84M | ||
| GainLossOnInvestmentSecurities | -3.63M | 11.84M | ||
| NetIncomeFromContinuingOperations | -24.59M | -56.20M | -25.33M | -14.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ANVS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|